Session Type: Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). Clinical trial with TCZ in GCA was performed with intravenous (iv) TCZ in a phase 2 trial (1), and with subcutaneous (sc) TCZ in the phase 3 GiACTA (2). There is general agreement on the initial/maintenance dose, but duration of TCZ therapy is not well established. In GiACTA trial, after one year on TCZ, most patients had GCA relapse after withdrawal.
This study aims to assessthe predictive factors of relapse in GCA in a clinical practice scenario.
Methods: Multicentre observational study of 471 patients with GCA. The diagnosis of GCA was performed between 2016 and 2021 according to: a) ACR criteria, and/or b) temporal artery biopsy, and/or c) imaging techniques. Relapse was defined according to EULAR consensus definition (3). From the 471 patients, we selected the patients who had available the data on relapse during follow-up. Multivariable study was conducted to identify the best set of predictors for the appearance of a relapse.
Results: GCA relapses were observed in 63 of 405 (15%) patients for whom such data was available(Table). No significant differences were observed between the two groups in demographic, clinical and laboratory characteristics or in prednisone dose at initiation of TCZ. The set of variables associated with GCA relapses were prior use of synthetic conventional disease-modifying antirheumatic drugs (scDMARDs), use of iv.TCZ, shorter time on TCZ therapy and optimization of TCZ dose (Figure).
Conclusion: GCA relapse seems related mainly to TCZ schedule and was associated with iv TCZ, and a shorter treatment time and optimization. References:
- Villiger PM, et al. Lancet. 2016. PMID: 26952547
- Stone JH, et al. N Engl J Med. 2017. PMID: 28745999
- Hellmich B, et al. Ann Rheum Dis. 2020. PMID: 31270110
To cite this abstract in AMA style:López F, Loricera J, Ferraz Amaro I, Castañeda S, Moriano Morales C, Narvaez J, Aldasoro V, Maiz O, Melero-Gonzalez R, Villa J, VELA P, Romero Yuste S, Callejas J, De Miguel E, Galindez-Agirregoikoa E, Sivera F, Fernández López J, Llobell A, Sánchez-Martín J, Goercke C, Sanchez-Bilbao L, Hernández J, Blanco R. Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/relapse-in-giant-cell-arteritis-treated-with-tocilizumab-predictive-factors/. Accessed .
« Back to ACR Convergence 2023
ACR Meeting Abstracts - https://acrabstracts.org/abstract/relapse-in-giant-cell-arteritis-treated-with-tocilizumab-predictive-factors/